IMUX (Immunic, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by IMUX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-18 | Robert Thorvald Nagel | Director | A | — | — |
| 2026-09-18 | BVF INC/IL | Director | A | — | — |
| 2026-08-10 | Elena Ridloff | Director | A | — | — |
| 2026-07-07 | Simona Skerjanec | Director | A | — | — |
| 2026-07-07 | Richard Alan Rudick | Director | A | — | — |
| 2026-07-07 | Joerg Neermann | Director | A | — | — |
| 2026-07-07 | BARCLAY A PHILLIPS | Director | A | — | — |
| 2026-07-07 | Jon Congleton | Director | A | — | — |
| 2026-06-29 | TAMAR D HOWSON | Director | A | — | — |
| 2026-06-29 | Joerg Neermann | Director | A | — | — |
| 2026-06-29 | Daniel Vitt | Director | A | — | — |
| 2026-06-29 | Richard Alan Rudick | Director | A | — | — |
| 2026-06-29 | MICHAEL W BONNEY | Director | A | — | — |
| 2026-06-29 | Jason Tardio | President and COO | A | — | — |
| 2026-06-29 | Glenn Whaley | Chief Financial Officer | A | — | — |
| 2026-06-29 | Jon Congleton | Director | A | — | — |
| 2026-06-29 | BARCLAY A PHILLIPS | Director | A | — | — |
| 2026-06-29 | Simona Skerjanec | Director | A | — | — |
| 2026-06-01 | Erik Lundgren | Chief Executive Officer | A | — | — |
| 2026-04-29 | Michael A. Panzara | Chief Medical Officer | A | — | — |
| 2025-07-18 | Daniel Vitt | CEO and Director | A | — | — |
| 2025-07-18 | Glenn Whaley | Chief Financial Officer | A | — | — |
| 2025-07-18 | Duane Nash | Executive Chairman | A | — | — |
| 2025-07-18 | Jason Tardio | President and COO | A | — | — |
| 2025-07-18 | Andreas Muehler | Chief Medical Officer | A | — | — |
| 2025-06-20 | Daniel Vitt | CEO and Director | Buy | — | — |
| 2025-06-20 | Jason Tardio | President and COO | Buy | — | — |
| 2025-06-20 | Andreas Muehler | Chief Medical Officer | A | — | — |
| 2025-06-20 | Duane Nash | Executive Chairman | A | — | — |
| 2025-06-20 | Glenn Whaley | Chief Financial Officer | A | — | — |
| 2025-06-16 | Duane Nash | Executive Chairman | Buy | — | — |
| 2025-06-09 | Glenn Whaley | Chief Financial Officer | A | — | — |
| 2025-06-09 | Joerg Neermann | Director | A | — | — |
| 2025-06-09 | Duane Nash | Executive Chairman | A | — | — |
| 2025-06-09 | Richard Alan Rudick | Director | A | — | — |
| 2025-06-09 | BARCLAY A PHILLIPS | Director | A | — | — |
| 2025-06-09 | Andreas Muehler | Chief Medical Officer | A | — | — |
| 2025-06-09 | Monika Maria Toernsen | Director | A | — | — |
| 2025-06-09 | TAMAR D HOWSON | Director | A | — | — |
| 2025-06-09 | Simona Skerjanec | Director | A | — | — |
| 2025-06-09 | Jason Tardio | President and COO | Buy | — | — |
| 2025-06-06 | Daniel Vitt | CEO and Director | Buy | — | — |
| 2025-06-05 | Joerg Neermann | Director | Buy | — | — |
| 2025-06-04 | Richard Alan Rudick | Director | Buy | — | — |
| 2025-06-04 | Glenn Whaley | Chief Financial Officer | MIXED | — | — |
| 2024-12-09 | Duane Nash | Executive Chairman | A | — | — |
| 2024-12-06 | Glenn Whaley | Chief Financial Officer | A | — | — |
| 2024-12-06 | Duane Nash | Executive Chairman | A | — | — |
| 2024-12-06 | Daniel Vitt | CEO and Director | A | — | — |
| 2024-12-06 | Andreas Muehler | Chief Medical Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 42,762 | — |
| — | CEO and Director | 39,188 | — |
| — | Chief Medical Officer | 29,799 | — |
| — | Chief Operating Officer | 27,948 | — |
| — | Director | 23,038 | — |
| — | Director | 20,000 | — |
| — | Chief Financial Officer | 9,551 | — |
| — | Executive Chairman | 3,603 | — |
| — | President and COO | 1,251 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the IMUX quote page; the site-wide leaderboard is on the insider transactions hub.